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Background
In mammals, the ability to sense and respond to both
intracellular and extracellular nutrient levels requires the
integration and cooperation of multiple complex
metabolic regulatory networks. Key among these are the
mTOR and AMPK signaling pathways, which are activated
in response to increased or decreased cellular energy
levels, respectively. These pathways control cell growth,
proliferation, metabolism and autophagy, and their dysre-
gulation has been associated with both cancer and meta-
bolic disease. The anti-diabetes drug metformin has been
shown to function, at least in part, through activation
of AMPK, however it also inhibits mTORC1 signaling,
suggesting a potential role for mTORC1 inhibition in the
beneficial effects of metformin. AMPK can suppress
mTORC1 through activation of the TSC complex, an inhi-
bitor of mTORC1, or inhibition of Raptor, an essential
component of mTORC1. The liver plays a critical role in
the maintenance of systemic metabolic homeostasis, and is
thought to be the major target organ for the physiological
effects of metformin, thus we are investigating the hepatic
regulation of mTORC1 by metformin.
Materials and methods
The effects of metformin on mTORC1 were assessed
in livers and primary hepatocytes from LTSC1KO mice
that have conditional loss of TSC1 in the liver. mTORC1
activity was determined by analysis of the phosphorylation
state of its targets, and the rate of protein synthesis using
35S-methionine incorporation. Physiological effects of
metformin were determined using glucose and metformin
tolerance tests.
Results
Dose-response and time-course assessments of mTORC1
activity in response to metformin show that inhibition of
mTORC1 signaling is resistant to metformin in primary
hepatocytes of LTSC1KO mice under conditions that
fully suppress mTORC1 signaling in control hepatocytes.
T h er a t eo fp r o t e i ns y n t h e s i si sa l s om a i n t a i n e da ta
higher level in these hepatocytes. Furthermore, while
metformin results in decreased phosphorylation of
mTORC1 targets in the livers of control mice, its activa-
tion is not as severely compromised in livers of
LTSC1KO mice. However, conditional loss of TSC1 in
the liver seems to have no effect on the systemic glucose
lowering ability of metformin.
Conclusions
Our findings demonstrate that conditional disruption of
the TSC1-TSC2 complex desensitizes hepatocytes to the
inhibition of mTORC1 by metformin, suggesting a domi-
nant role for this tumor suppressor complex in the hepatic
control of mTORC1 by energy stress. We are continuing
to use this genetic model to determine the contribution of
mTORC1 inhibition by metformin in the liver to the cellu-
lar and physiological effects of metformin.
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